The FDA has accepted for priority review a supplemental biologics license application (sBLA) for teplizumab-mzwv (Tzield; Sanofi) that seeks to expand the current age indication from 8 years and older …
Copyright MatchingDonors.com © 2026 All rights reserved.
Daily Diabetes News is published by MatchingDonors.com.